🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Long term survival is a real phenomenon for ES-SCLC but in a small % Stephen V Liu, MD #BTOG25

A review on maintenance therapy for #SCLC with Dr. Luis Paz-Ares now Clinical Lung Cancer outlining the rationale, prior efforts, and future prospects for adding therapy after induction chemotherapy but before progression. clinical-lung-cancer.com/article/S1525-…

Our Disparities Research Section Editor camille ragin (Fox Chase Cancer Center) is a co-author on this new commentary, "Remedying Black cancer disparities with clinical research prioritization." acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… Nadine J. Barrett, PhD, MA., MS Dr. Hayley S. Thompson Timiya S. Nolan, PhD, APRN-CNP, FAAN Vanessa B. Sheppard, PhD OncoAlert

Failure to ethnically diversify clinical trials can lead to missed signals for efficacy and safety. Researchers need to develop well thought through recruitment plans to diversify enrolment by ethnicity bmj.com/content/388/bm…

New commentary examines caregiver experiences during early phase clinical oncology trials & provides recommendations to strengthen support to caregivers and, by extension, those living with cancer. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… Debra Lundquist, PhD, RN Rachel Jimenez, MD OncoAlert

System-Level Transformations to Increase Patient Participation in Clinical Trials. ascopubs.org/doi/10.1200/OP… ASCO Journal of Clinical Oncology JCO Oncology Practice #Cancer #ClinicalTrials #CancerResearch Gabrielle UAB O'Neal Comprehensive Cancer Center

5 year outcomes with 1L cemiplimab vs chemo in PD-L1 high NSCLC from phase III EMPOWER-Lung 1 JTO & JTO CRR. OS favors cempilimab (26.1 vs 13.3m, HR 0.59, 5y OS rate 29% vs 15%) with better outcomes for PD-L1 ≥ 90%, where mOS 38.8m, 5y OS rate 39.8%. jto.org/article/S1556-…

🔊NEW PODCAST 🔊 Is #DEI Dead? The Future of Diversity, Equity + Inclusion in #Healthcare Join the #OJC debate with Craig Underhill, Dr. Kate Clarke + Prof. Chris Jackson Listen t.ly/ddJ3e or wherever you get podcasts ASCO National Cancer Institute NIH The Lancet nature Martin Stockler

Are you planning on discussing a cancer randomized clinical trial in a conference, grand rounds, or any academic setting? Take a look at our Common Sense Oncology guideline for discussants of RCT! doi.org/10.1016/j.ejca…

EGFR mutation is no more a straightforward story. 3 options in 1L, many options in 2L. perez oliveros #ELCC25

Adagrasib 400 mg + Pembrolizumab impressive mPFS in KRAS G12C mutant NSCLC and PDL1 >50% and good safety. Better than IO or CT+IO alone. Good chemo free strategy for patients Await for ph3 trial. #ELCC2025

Eloquent piece by Dana-Farber Dr Abrahm re #burnout. Thank you for illuminating our ASCO #Well-being Task Force work! Julie Gralow Clifford Hudis Grief’s Hidden Role in Oncologist Compassion Fatigue and Burnout targetedonc.com/view/grief-s-h… via Targeted Oncology

Tomorrow: Paths to Equitable Care – Inclusion as the Default Hosted by SPHERE & the Nursing Research Institute Keynote: Prof Calvin Moorley, London South Bank Uni In-person (Darlinghurst) or online: thesphere.com.au/events/paths-t…

⭐️ NEW PUBLICATION⭐️In 2024 @iaslc's JTO published a debate on the role of #equipoise in Ph3 RCTs of precision oncology therapeutics in #NSCLC. (See prior 🧵x.com/CancerEthicsDo…) In a new letter we highlight key implications if equipoise is uncertain in a given RCT...

lol reading this piece by David Johnston - some deep truths ascopubs.org/doi/10.1200/OP…

“They were unsure whether the conversation we had was real or a dream... so wanted to make sure the advice was correct.” Doctors worked to the brink of human capacity but NSW Govt says the strike is unsafe, not the dangerous workloads every other day. thesaturdaypaper.com.au/news/health/20…

Touching story of Dr Lynham’s family. In a country like ours, everyone should have access to clinical trials. More money and one stop shop aren’t the answers. This requires cultural reform of the whole sector. Who is in charge BTW? abc.net.au/news/2025-04-1…

Researchers from Peter Mac will collaborate with colleagues across Australia to evaluate the use of serial liquid biopsies for people with lung cancer with the $14.7M MRFF-funded ASPiRATION-2 Liquid trial. More: petermac.org/about-us/news-…

Results from Copenhagen Prospective Personalized Oncology (CoPPO) Annals of Oncology - over 2000 pts in phase I clinic had comprehensive NGS and 57% had an actionable alteration. Though some more actionable than others: CEACAM5 35%, HRD 20%, TMB 5%. annalsofoncology.org/article/S0923-…

Oncologist around the world are embracing LLM/AI in their daily practice. In our recent publication we evaluated physician and patient letter generation and the results were supportive! Link below. ascopubs.org/doi/10.1200/CC…